Research Topics
Species | William CarpenterSummaryAffiliation: University of Maryland Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Psychotic disorders in DSM-5: Summary of changesWilliam T Carpenter
Department of Psychiatry and Pharmacology, Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD, USA The VISN 5 MIRECC, Veterans Administration, Baltimore, MD, USA Electronic address
Asian J Psychiatr 6:266-8. 2013..The specific nature of these revisions in the DSM-5 criteria for schizophrenia and other psychotic disorders along with their rationale are summarized in this article...- Another view of the history of antipsychotic drug discovery and developmentW T Carpenter
Department of Psychiatry, Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD, USA
Mol Psychiatry 17:1168-73. 2012..New clinical and basic neuroscience paradigms may guide the near future and provide a more heuristic construct for novel and innovative discovery... 
Diazepam treatment of early signs of exacerbation in schizophreniaW T Carpenter
Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland, Baltimore 21228, USA
Am J Psychiatry 156:299-303. 1999..This study examined diazepam efficacy for this phase of treatment...- At issue: A model for academic/industry collaborationWilliam T Carpenter
Department of Psychiatry, University of Maryland School of Medicine, Maryland Psychiatric Research Center, PO Box 21247, Baltimore, MD 21228, USA
Schizophr Bull 30:997-1004. 2004..We discuss the principles involved and the resolutions achieved in the hope that it may provide a useful model for addressing academic/industry scientific collaborations... 
Evidence-based therapeutics--introducing the Cochrane cornerWilliam T Carpenter
Schizophr Bull 33:633-4. 2007- The evolution of drug development in schizophrenia: past issues and future opportunitiesWilliam T Carpenter
Department of Psychiatry, Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
Neuropsychopharmacology 33:2061-79. 2008..Success in drug discovery for cognition and negative symptom pathologies may bring forth issues in ethics as the potential for enhancing normal function is explored... - Lessons to take home from CATIEWilliam T Carpenter
Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21228, USA
Psychiatr Serv 59:523-5. 2008..Bottom line: the dichotomy between first- and second-generation antipsychotics was not supported by efficacy data (and now, is not supported effectiveness data). Only clozapine has documented superiority in treatment-resistant cases... - Commentary on the Soteria project: misguided therapeuticsWilliam T Carpenter
Maryland Psychiatric Research Center, University of Maryland, School of Medicine, Baltimore 21228, USA
Schizophr Bull 28:577-81; discussion 583-8. 2002 - The psychoses: cluster 3 of the proposed meta-structure for DSM-V and ICD-11W T Carpenter
Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
Psychol Med 39:2025-42. 2009..In an effort to group mental disorders on the basis of etiology, five clusters have been proposed. Here we consider the validity of the cluster comprising selected psychotic and related disorders... - Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeksW T Carpenter
Maryland Psychiatric Research Center and the Department of Psychiatry, University of Maryland School of Medicine, Baltimore 21228, USA
Am J Psychiatry 156:412-8. 1999..The authors tested a new dose reduction approach: increasing the interval between injections during intramuscular decanoate antipsychotic treatment... - Sense and nonsense: an essay on schizophrenia research ethicsW T Carpenter
Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore 21228, USA
Schizophr Res 35:219-25; discussion 227-36. 1999.... - Decisional capacity for informed consent in schizophrenia researchW T Carpenter
Maryland Psychiatric Research Center and the Department of Psychiatry, University of Maryland, Baltimore 21228, USA
Arch Gen Psychiatry 57:533-8. 2000.... - From clinical trial to prescriptionWilliam T Carpenter
Maryland Psychiatric Research Center, PO Box 21247, Baltimore, MD 21228, USA
Arch Gen Psychiatry 59:282-5. 2002..Most hotly debated is the role of money in the creation and dissemination of knowledge... - Commentary: how the doctor can counter commercial bias in the dissemination of pharmacotherapeutic knowledgeWilliam T Carpenter
Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD21228, USA
J Nerv Ment Dis 190:593-6. 2002 - Clinical constructs and therapeutic discoveryWilliam T Carpenter
University of Maryland Baltimore, Maryland Psychiatric Research Center, PO Box 21247, Baltimore, MD 21228, USA
Schizophr Res 72:69-73. 2004..Antipsychotic drugs fail to address these pathologies. These unmet treatment needs are clinical targets for drug discovery involving novel therapeutic pathways... - The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumesCelso Arango
Maryland Psychiatric Research Center, Department of Psychariatry, University of Maryland, MD 21228, USA
Am J Psychiatry 160:1421-7. 2003.... - The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairmentsRobert W Buchanan
Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
Am J Psychiatry 164:1593-602. 2007..Agents that act at the glycine site of the N-methyl-D-aspartic acid (NMDA) glutamatergic receptor have been suggested as promising treatments for moderate to severe negative symptoms and cognitive impairments... - Identifying unmet therapeutic domains in schizophrenia patients: the early contributions of Wayne Fenton from Chestnut LodgeThomas H McGlashan
Department of Psychiatry, Yale University, USA
Schizophr Bull 33:1086-92. 2007..The results have radically changed the paradigm for discovery with emphasis on impaired cognition and negative symptom psychopathology... - Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to dateAlex S Cohen
Department of Psychology, University of Maryland, College Park, USA
Schizophr Bull 33:1201-12. 2007..The question of whether deficit patients exhibit a unique cognitive impairment profile will require a more sophisticated and rigorous examination of the neuropsychology of the deficit syndrome... - Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophreniaDeanna L Kelly
Maryland Psychiatric Research Center, University of Maryland, Baltimore, Maryland 21228, USA
Ann Clin Psychiatry 15:181-6. 2003..High doses of olanzapine during 8 weeks of treatment did not increase lipids and liver enzymes like clozapine did. Olanzapine at 50 mg/day may be associated with more anticholinergic effects and weight gain than clozapine... - Olanzapine treatment of residual positive and negative symptomsRobert W Buchanan
Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland, Baltimore 21228, USA
Am J Psychiatry 162:124-9. 2005..The authors examined the comparative efficacy and safety of olanzapine and haloperidol in outpatients with partially responsive schizophrenia... - White matter alterations in deficit schizophreniaLaura M Rowland
Department of Psychiatry, Maryland Psychiatric Research Center, University of Maryland School of Medicine, P O Box 21247, Baltimore, MD 21228, USA
Neuropsychopharmacology 34:1514-22. 2009..These findings provide further support for altered frontal-parietal network in deficit schizophrenia... - Correlations between rCBF and symptoms in two independent cohorts of drug-free patients with schizophreniaAdrienne C Lahti
Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
Neuropsychopharmacology 31:221-30. 2006..The involvement of both frontal and parietal regions is implicated in the pathophysiology of negative symptoms... - The Declaration of Helsinki and clinical trials: a focus on placebo-controlled trials in schizophreniaWilliam T Carpenter
Maryland Psychiatric Research Center, Univeristy of Maryland School of Medicine, USA
Am J Psychiatry 160:356-62. 2003..The authors' goal was to consider ethical approaches to placebo-controlled clinical trials in the light of the evolving Declaration of Helsinki, with special attention to applications to research on schizophrenia... - First-episode schizophrenia: a focus on pharmacological treatment and safety considerationsDeanna L Kelly
Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland 21228, USA
Drugs 65:1113-38. 2005.... - Dihydropyrimidinase-related protein 2 (DRP-2) gene and association to deficit and nondeficit schizophreniaL Elliot Hong
Department of Psychiatry, Maryland Psychiatric Research Center, School of Medicine, University of Maryland, Baltimore, 21228, USA
Am J Med Genet B Neuropsychiatr Genet 136:8-11. 2005..2%, P =0.050) forms of schizophrenia compared to controls (allele frequency 25.0%). We conclude that the DRP-2 *2236 C allele may mark another polymorphism in DRP-2, or in a nearby gene, that may influence susceptibility to schizophrenia... - Optimistic bias in the perception of personal risk: patterns in schizophreniaKristen J Prentice
Maryland Psychiatric Research Center, P O Box 21247, Baltimore, MD 21228, USA
Am J Psychiatry 162:507-12. 2005..The authors investigated whether schizophrenia patients share the same optimistic biases frequently demonstrated by non-ill adults in their perceptions of personal risk... - Summer birth and deficit schizophrenia: a pooled analysis from 6 countriesErick Messias
Department of Psychiatry, School of Medicine, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA
Arch Gen Psychiatry 61:985-9. 2004..CONCLUSIONS: Deficit schizophrenia has a season of birth pattern that differs from that of nondeficit schizophrenia. This analysis supports the notion of a separate disease within schizophrenia... - Remission in schizophrenia: proposed criteria and rationale for consensusNancy C Andreasen
Department of Psychiatry, University of Iowa, Iowa City, Iowa, USA
Am J Psychiatry 162:441-9. 2005..These criteria should facilitate research and support a positive, longer-term approach to studying outcome in patients with schizophrenia... - Feasibility of reducing the duration of placebo-controlled trials in schizophrenia researchRobert P McMahon
Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland Baltimore Medical School, Baltimore, MD, USA
Schizophr Bull 34:292-301. 2008..Shortening placebo-controlled trials would reduce patient burden and ethical objections to prolonged administration of placebo and reduce potential bias due to high dropout rates in longer clinical trials... - Maintaining informed consent validity during lengthy research protocolsKristen J Prentice
University of Maryland School of Medicine, USA
IRB 29:1-6. 2007 - Will the Kraepelinian dichotomy survive DSM-V?Bernard A Fischer
Department of Psychiatry, Maryland Psychiatric Research Center, VA Capitol Health Care Network VISN 5 MIRECC and University of Maryland School of Medicine, Baltimore, MD 21228, USA
Neuropsychopharmacology 34:2081-7. 2009..An alternative paradigm based on domains of pathology is more powerful for studies of etiology, pathophysiology, and therapeutic discovery... - Neuroplasticity and schizophreniaDouglas O Frost
Department of Pharmacology and Experimental Therapeutics, Baltimore, Maryland, USA
Biol Psychiatry 56:540-3. 2004..Although the focus of this workshop was schizophrenia, the phenomena considered are pertinent to other disorders, such as depression and drug abuse... - The costs of drugs for schizophreniaRobert Freedman
Am J Psychiatry 163:2029-31. 2006 - Another view of therapy for cognition in schizophreniaWilliam T Carpenter
Biol Psychiatry 51:969-71. 2002 - The NIMH-MATRICS consensus statement on negative symptomsBrian Kirkpatrick
Department of Psychiatry and Health Behavior, Medical College of Georgia, USA
Schizophr Bull 32:214-9. 2006 - Clarifying standards for using placebosRobert J Levine
Science 300:1659-61. 2003 - Treatment of schizophrenia negative symptoms: future prospectsStephen M Erhart
UCLA Department of Psychiatry and Biobehavioral Sciences, USA
Schizophr Bull 32:234-7. 2006..We review the continuing limitations in treatment and discuss possible sources of heterogeneity among negative symptoms. We also anticipate conceptual uncertainties that may arise with forthcoming treatment developments... - Targeting schizophrenia research to patient outcomesWilliam T Carpenter
Am J Psychiatry 163:353-5. 2006 - Challenge to atypical antipsychotic drug effect on cognitionWilliam T Carpenter
Am J Psychiatry 164:1910-1; author reply 1911-2. 2007 - The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover studyRobert R Conley
J Clin Psychopharmacol 23:668-71. 2003 - The deficit syndrome in schizophrenia: implications for the treatment of negative symptomsCelso Arango
Servicio de Psiquiatria, Hospital General Gregorio Maranon, C Ibiza 43, 280079 Madrid, Spain
Eur Psychiatry 19:21-6. 2004..The loss of precious human experiences and the association with poor long-term functional outcome justifies a focused and dedicated effort to discover the causes and treatments of this distinctive aspect of schizophrenia... - First- and second-generation antipsychotics: learning from CUtLASS and CATIERajiv Tandon
Arch Gen Psychiatry 64:977-8; author reply 979-80. 2007 - The schizophrenia paradigm: a hundred-year challengeWilliam T Carpenter
J Nerv Ment Dis 194:639-43. 2006 - Traditional ethics and new sensitivitiesWilliam T Carpenter
Schizophr Bull 32:1-2. 2006 - Association between polymorphism of the SNAP29 gene promoter region and schizophreniaIkwunga Wonodi
Schizophr Res 78:339-41. 2005 - Schizophrenia: disease, syndrome, or dimensions?William T Carpenter
Fam Process 46:199-206. 2007..This view has been challenged by a series of studies during the past three decades. These investigations are summarized in this report. Implications for clinical work with families are considered... - Was Joan of Arc criminally, responsible for her acts alleged of heresy?Karen Sullivan
Bard College, Annandale on Hudson, New York, USA
Pharos Alpha Omega Alpha Honor Med Soc 67:4-11. 2004
Research Grants
- Multidisciplinary Schizophrenia Research TrainingWilliam Carpenter; Fiscal Year: 2007..abstract_text> ..
- RESEARCH ETHICS IN SCHIZOPHRENIAWilliam Carpenter; Fiscal Year: 2007....
- RESEARCH ETHICS IN SCHIZOPHRENIAWilliam Carpenter; Fiscal Year: 2003..The proposed work will provide a major source of scientific data of relevance to the current debate on ethics of schizophrenia research. ..
- TREATMENT OF NEGATIVE SYMPTOMS & COGNITIVE IMPAIRMENTSWilliam Carpenter; Fiscal Year: 2003..The study will provide new information on the efficacy of d- cyclosporine and glycine for both persistent primary and secondary negative symptoms and its effect on cognitive functioning. ..